Cuba Biotechnology Company ®
helix image
www.cubabiotechnology.com

Home Page Contact Us Links Advertise Jobs
Classifieds Events Partners Services Editorials
Vaccines

Vitilgo is non-atrophic hypopigmentation of the skin. The lesions begin as macules and may become confluent. Biopsy of these lesions reveals an absence of melanocytes. Vitiligo has been associated with diabetes, hypothroidism, Addison's disease, pernicious anemia, and candidiasis. It is also a component of the Vogt-Koyanagi-Harada syndrome.

There are various treament regimens for vitiligo: (1) a trial of high-potency topical steroids, (2) natural sunlight, or (3) PUVA therapy.

In Cuba, through the 30 plus years research and commercial development efforts of Carlos Miyares Cao, M.D. and others, the pharmaceutical, Melagenina, is marketed for use in patients with vitiligo. Melagenina stimulates reproduction of melanocytes and synthesis of melanin and treatmentis exclusively offered by the Institute of Placenta-Histotherapy. In its original version (Melagenina), the drug was applied 3 times a day (every 8 hours) supported by a special UV-phototherapy. Newly developed Melagenina Plus needs to be applied only once a day. Intense Sunlight or even UV-Light should be avoided.

medicine image

This medication is not available in the USA due to the Embargo against importation of Cuban biotechnology products into the USA.

Interferon
EGF
PPG
Antibodies
AIDS
Vitiligo
Streptokinase
Oncology
New Areas
CyberCuba ® Cuba Morning Star ™ Cuba Aficionado ® Mi Malecon Global Denver
Ms Cuba ® AIDS in Cuba Havana Bay Company ® Dixie Cuba Internet Physician

havana bay logo®

email image Cuba Biotechnology Company®

© Copyright 1997-2016